Clustering of Brain Function Network Based on Attribute and Structural Information and Its Application in Brain Diseases

At present, the diagnosis of brain disease is mainly based on the self-reported symptoms and clinical signs of the patient, which can easily lead to psychiatrists' bias. The purpose of this study is to develop a brain network clustering model to accurately identify brain diseases based on resti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neuroinformatics Vol. 13; p. 79
Main Authors Cui, Xiaohong, Xiao, Jihai, Guo, Hao, Wang, Bin, Li, Dandan, Niu, Yan, Xiang, Jie, Chen, Junjie
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 07.02.2020
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:At present, the diagnosis of brain disease is mainly based on the self-reported symptoms and clinical signs of the patient, which can easily lead to psychiatrists' bias. The purpose of this study is to develop a brain network clustering model to accurately identify brain diseases based on resting state functional magnetic resonance imaging (fMRI) in the absence of clinical information. We use cosine similarity and sub-network kernels to measure attribute similarity and structure similarity, respectively. By integrating the structure similarity and attribute similarity into one matrix, spectral clustering is used to achieve brain network clustering. Finally, we evaluate this method on three diseases: Alzheimer's disease, Bipolar disorder patients, and Schizophrenia. The performance of methods is evaluated by measuring clustering consistency. Clustering consistency is similar to clustering accuracy, which is used to evaluate the consistency between the clustering labels and clinical diagnostic labels of the subjects. The experimental results show that our proposed method can significantly improve clustering performance, with a consistency of 60.6% for Alzheimer's disease, with a consistency of 100% for Schizophrenia, with a consistency of 100% for Bipolar disorder patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Edited by: Xi-Nian Zuo, Institute of Psychology (CAS), China
Reviewed by: Daoqiang Zhang, Nanjing University of Aeronautics and Astronautics, China; Sam Neymotin, Nathan Kline Institute for Psychiatric Research, United States; Yi Su, Banner Alzheimer's Institute, United States
ISSN:1662-5196
1662-5196
DOI:10.3389/fninf.2019.00079